Cellectar Biosciences (NASDAQ:CLRB) reported quarterly losses of $(0.53) per share which beat the analyst consensus estimate of $(2.29) by 76.89 percent. This is a 76.67 percent decrease over losses of $(0.30) per share from the same period last year.